FEM-PrEP https://validator.w3.org/feed/docs/rss2.html Identifying factors that influence pregnancy intentions: evidence from South Africa and Malawi Prevalence and Incidence estimation of HSV-2 in HIV high risk South-African women determined by two IgG ELISA methods Socio-Behavioral Aspects of FEM-PrEP Safety Pregnancy and Contraceptive Effectiveness in the FEM-PrEP Trial Drug Resistance Community Engagement Adherence Key Findings About FEM-PrEP Questions and Answers FEM-PrEP June 2011 Update FEM-PrEP June 2011 Update Summary Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: Results of a Consultation with community stakeholders Widow cleansing and inheritance among the Luo in Kenya: the need for additional women-centered HIV prevention options Implementing Good Participatory Practice Guidelines in the FEM-PrEP Clinical Trial: A Focus on Local Stakeholder Involvement FEM-PrEP: Adherence patterns and factors associated with adherence to a daily, oral study product for pre-exposure prophylaxis Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials Preexposure prophylaxis for HIV infection among African women Home Sample Page Assessing Physical Delivery of PrEP in Support of Proof of Deliverability Related Research & Information Contact Information Investigators, staff, and collaborators Early Closure Fact Sheets Publications What was FEM-PrEP? Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial Using GIS to Support Decision Making for Service Delivery: Planning for the Implementation of a New HIV-Prevention Pill in Rural Kenya Human Resource Challenges to Integrating Pre-Exposure Prophylaxis (PrEP) into the Public Health System in Kenya Intermittent behavioral risk reduction as a realistic scenario for potential pre-exposure prophylaxis (PrEP) users: A qualitative study among high-risk women in Bondo, Kenya Verification of Chemistry Reference Ranges using a Simple Method in Sub-Saharan Africa during a Phase III Clinical Trial High presence of CXCR4-using viruses in new HIV-1 non B-subtype infections: a retrospective analysis of a pre-exposure prophylaxis trial in women Medroxyprogesterone acetate levels among women using depot medroxyprogesterone acetate in the FEM-PrEP Trial Participants’ explanations for non-adherence in the FEM-PrEP clinical trial Perception of HIV risk and adherence to a daily, investigational product for HIV prevention in FEM-PrEP Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract Elevated liver transaminases, human immune deficiency virus (HIV) seroconversion and rapid progression to AIDS in a HIV prevention clinical trial participant: A case report Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: A new measure of antiretroviral adherence? Neurological Syndrome in an HIV-Prevention Trial Volunteer Randomized to Daily Tenofovir Disoproxil Fumarate (300 mg) and Emtricitabine (200 mg) in Bondo, Kenya A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya and Pretoria, South Africa The sexual risk context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa Liver and Renal Safety of Tenofovir Disoproxil Fumarate in Combination with Emtricitabine among African Women in a Pre-exposure Prophylaxis Trial Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on contraceptive efficacy in Bondo, Kenya Pregnancy and contraceptive use among women participating in the FEM-PrEP trial Drug resistance and plasma viral RNA level after suboptimal use of oral pre-exposure prophylaxis in women The science of being a study participant: FEM-PrEP participants’ explanations for over-reporting adherence to the study pills and on the whereabouts of unused pills Facilitators of adherence to the study pill in the FEM-PrEP clinical trial